222 related articles for article (PubMed ID: 24828987)
1. Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma.
Gandolfi G; Sancisi V; Piana S; Ciarrocchi A
Int J Cancer; 2015 Sep; 137(5):1001-11. PubMed ID: 24828987
[TBL] [Abstract][Full Text] [Related]
2. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
3. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
4. BRAF overexpression is associated with BRAF V600E mutation in papillary thyroid carcinomas.
da Silva RC; de Paula HS; Leal CB; Cunha BC; de Paula EC; Alencar RC; Meneghini AJ; Silva AM; Gontijo AP; Wastowski IJ; Saddi VA
Genet Mol Res; 2015 May; 14(2):5065-75. PubMed ID: 26125698
[TBL] [Abstract][Full Text] [Related]
5. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
Gandolfi G; Sancisi V; Torricelli F; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A
J Clin Endocrinol Metab; 2013 May; 98(5):E934-42. PubMed ID: 23533235
[TBL] [Abstract][Full Text] [Related]
6. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
[TBL] [Abstract][Full Text] [Related]
8. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
[TBL] [Abstract][Full Text] [Related]
9. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.
de Biase D; Cesari V; Visani M; Casadei GP; Cremonini N; Gandolfi G; Sancisi V; Ragazzi M; Pession A; Ciarrocchi A; Tallini G
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1530-8. PubMed ID: 24780046
[TBL] [Abstract][Full Text] [Related]
10. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.
Givens DJ; Buchmann LO; Agarwal AM; Grimmer JF; Hunt JP
Laryngoscope; 2014 Sep; 124(9):E389-93. PubMed ID: 24604709
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
[TBL] [Abstract][Full Text] [Related]
12. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
[TBL] [Abstract][Full Text] [Related]
13. BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review).
Leonardi GC; Candido S; Carbone M; Raiti F; Colaianni V; Garozzo S; Cinà D; McCubrey JA; Libra M
Mol Med Rep; 2012 Oct; 6(4):687-94. PubMed ID: 22858857
[TBL] [Abstract][Full Text] [Related]
14. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
[TBL] [Abstract][Full Text] [Related]
15. The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma.
Guerra A; Sapio MR; Marotta V; Campanile E; Rossi S; Forno I; Fugazzola L; Budillon A; Moccia T; Fenzi G; Vitale M
J Clin Endocrinol Metab; 2012 Feb; 97(2):517-24. PubMed ID: 22170714
[TBL] [Abstract][Full Text] [Related]
16. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
[TBL] [Abstract][Full Text] [Related]
17. BRAFV600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas.
Lee JI; Jang HW; Kim SW; Kim JW; Oh YL; Chung JH
Head Neck; 2013 Apr; 35(4):548-53. PubMed ID: 22488961
[TBL] [Abstract][Full Text] [Related]
18. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
Li J; Liang J; Zhao T; Lin Y
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
[TBL] [Abstract][Full Text] [Related]
19. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z
Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]